EcoR1 Capital LLC raised its position in shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS) by 62.6% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 673,100 shares of the biotechnology company’s stock after buying an additional 259,100 shares during the period. Aclaris Therapeutics makes up 5.1% of EcoR1 Capital LLC’s holdings, making the stock its 8th largest position. EcoR1 Capital LLC’s holdings in Aclaris Therapeutics were worth $20,072,000 as of its most recent filing with the SEC.
A number of other institutional investors have also made changes to their positions in the stock. Nexthera Capital LP acquired a new position in shares of Aclaris Therapeutics during the first quarter worth about $3,325,000. Schwab Charles Investment Management Inc. increased its position in shares of Aclaris Therapeutics by 6.6% in the first quarter. Schwab Charles Investment Management Inc. now owns 43,961 shares of the biotechnology company’s stock worth $1,311,000 after buying an additional 2,736 shares during the period. Citadel Advisors LLC acquired a new position in shares of Aclaris Therapeutics during the first quarter worth about $1,519,000. Lazard Asset Management LLC acquired a new position in shares of Aclaris Therapeutics during the first quarter worth about $1,443,000. Finally, UBS Group AG increased its position in shares of Aclaris Therapeutics by 60.4% in the first quarter. UBS Group AG now owns 4,462 shares of the biotechnology company’s stock worth $133,000 after buying an additional 1,681 shares during the period. 91.40% of the stock is owned by hedge funds and other institutional investors.
Aclaris Therapeutics, Inc. (NASDAQ ACRS) traded up 3.70% during midday trading on Friday, hitting $25.49. The stock had a trading volume of 511,777 shares. The stock has a 50-day moving average price of $25.42 and a 200 day moving average price of $28.31. Aclaris Therapeutics, Inc. has a one year low of $17.10 and a one year high of $33.25. The firm’s market cap is $681.42 million.
Aclaris Therapeutics (NASDAQ:ACRS) last announced its earnings results on Tuesday, May 9th. The biotechnology company reported ($0.48) earnings per share for the quarter, beating the consensus estimate of ($0.54) by $0.06. On average, analysts predict that Aclaris Therapeutics, Inc. will post ($3.11) earnings per share for the current year.
COPYRIGHT VIOLATION NOTICE: “EcoR1 Capital LLC Raises Stake in Aclaris Therapeutics, Inc. (ACRS)” was reported by sleekmoney and is the property of of sleekmoney. If you are reading this story on another site, it was illegally copied and reposted in violation of US and international copyright & trademark laws. The correct version of this story can be accessed at https://sleekmoney.com/ecor1-capital-llc-raises-stake-in-aclaris-therapeutics-inc-acrs/1916396.html.
A number of equities analysts recently issued reports on the company. Cantor Fitzgerald assumed coverage on Aclaris Therapeutics in a report on Friday. They issued an “overweight” rating and a $50.00 price target for the company. ValuEngine raised Aclaris Therapeutics from a “sell” rating to a “hold” rating in a report on Thursday. Jefferies Group LLC reaffirmed a “buy” rating and issued a $36.00 price target on shares of Aclaris Therapeutics in a report on Thursday, May 25th. Zacks Investment Research downgraded Aclaris Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, May 12th. Finally, Guggenheim reaffirmed a “buy” rating and issued a $40.00 price target on shares of Aclaris Therapeutics in a report on Thursday, April 6th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $39.00.
About Aclaris Therapeutics
Aclaris Therapeutics, Inc is a United States-based clinical-stage specialty pharmaceutical company. The Company is focused on identifying, developing and commercializing drugs to address the needs in dermatology. Its lead drug candidate, A-101 Topical Solution, is a hydrogen peroxide topical solution that the Company is developing as a prescription treatment for seborrheic keratosis (SK).
Want to see what other hedge funds are holding ACRS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aclaris Therapeutics, Inc. (NASDAQ:ACRS).
This story was originally published by sleekmoney (https://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://sleekmoney.com/ecor1-capital-llc-raises-stake-in-aclaris-therapeutics-inc-acrs/1916396.html
Receive News & Ratings for Aclaris Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.